GLP-1 agonists, such as Ozempic and Wegovy, may offer new pathways for treating addiction by targeting the lateral septum, a brain region responsible for reward cravings. While originally developed for type 2 diabetes and weight loss, research suggests these drugs reduce consumption of alcohol, nicotine, and other substances by modulating how the brain processes reward stimuli and communicates with dopamine-producing centers.
How do GLP-1 drugs impact addiction?
GLP-1 agonists work by mimicking the glucagon-like peptide-1 hormone. This hormone stimulates insulin release, slows digestion, and increases feelings of fullness. While these effects drive weight loss, recent human studies show these drugs also reduce alcohol consumption. Preclinical animal studies suggest the impact extends to cocaine, amphetamines, opiates, and nicotine.
For decades, neuroscientists focused on the ventral tegmental area (VTA) and the nucleus accumbens (NAc) to understand addiction. These regions produce dopamine, the neurotransmitter central to the brain’s reward circuitry. However, these areas lack a significant density of GLP-1 receptors, suggesting they are not the direct mechanism for the drugs’ anti-consumption effects.
Instead, researchers are looking “upstream” to the lateral septum. This structure is heavily loaded with GLP-1 receptors. Recent findings indicate that activating these receptors directly in the lateral septum reduces food consumption in mice, with similar results observed for alcohol consumption earlier this year.
In 1953, researchers Joseph Brady and Walle Nauta identified “septal rage,” a condition where animals with lateral septum damage showed increased aggression. This established the region’s historical link to emotional regulation.
Why is the lateral septum central to reward processing?
The lateral septum acts as a bridge between memory and reward. It receives primary input from the hippocampus, the region responsible for forming long-term episodic memories. The hippocampus utilizes “place cells”—neurons that fire based on a person’s position in space and time.
The lateral septum also contains place cells. These cells integrate “where and when” information from the hippocampus with “what is good in this place” data. This allows the brain to form a conscious perception of rewards. Neuroscientists now believe the lateral septum is the region that allows us to “think about” rewards before communicating that information to the dopamine-producing machinery in the brain.
New laboratory findings suggest that GLP-1 drugs reduce specific activity within the lateral septum. This reduction may prevent the region from communicating effectively with other parts of the brain, effectively dampening the intensity of cravings.
Comparing Reward Mechanisms
| Brain Region | Primary Function | Role in Addiction |
|---|---|---|
| Nucleus Accumbens | Dopamine production | The “feeling good” machinery. |
| Lateral Septum | Reward perception | The “thinking about reward” center. |
What substances could these drugs affect in the future?
The discovery of the lateral septum’s role shifts the focus of addiction treatment from merely managing dopamine to managing the conscious perception of cravings. If GLP-1 agonists can successfully interrupt the communication between the lateral septum and the reward system, they could become a primary tool for various dependencies.
Current research is moving from weight management toward broader applications in:
- Alcohol dependence: Building on human studies showing reduced intake.
- Nicotine addiction: Following preclinical evidence in animal models.
- Opioid and stimulant use: Targeting the neurological “thought” of the reward to prevent relapse.
As these drugs move through clinical trials, the medical community is watching to see if they can provide a non-surgical alternative for managing the neurological drivers of obesity and substance overuse.
Frequently Asked Questions
Can Ozempic be used to treat addiction?
While currently approved for diabetes and weight loss, research into its effects on the lateral septum suggests potential future applications for treating alcohol and substance addictions.
How does the lateral septum differ from the dopamine system?
The dopamine system (like the nucleus accumbens) handles the actual feeling of pleasure, while the lateral septum handles the mental anticipation and “thinking about” the reward.
What are GLP-1 agonists?
They are a class of drugs that mimic the GLP-1 hormone to regulate insulin, digestion, and appetite.
What are your thoughts on the future of addiction treatment?
Leave a comment below or subscribe to our newsletter for the latest updates in neuroscience and medical research.
Related reading